The new IDMO smart factory at Bridgewater in New Jersey is spread over 118,000ft². Credit: Cellares.

Integrated development and manufacturing organisation (IDMO) Cellares has raised $255m in a Series C financing round for a cell therapy development facility at Bridgewater in New Jersey, US.

New investor Koch Disruptive Technologies led the funding round and its managing director David Mauney will join Cellares’s board of directors.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The financing round saw participation from Bristol Myers Squibb, Willett Advisors and DFJ Growth, along with current investors Eclipse, Decheng Capital and 8VC. 

To be spread over 118,000ft², the new commercial-scale IDMO smart factory will feature robotics, tailored technology and interconnected software. 

The facility will manufacture 40,000 cell therapy batches annually.

IDMO smart factories use combined technologies to manufacture ten times more cell therapy batches annually versus standard CDMO plants, utilising the same labour and footprint. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cellares’s technology adoption partnership programme aids the collaboration of cell therapy developers in automating and transferring technology manual processes onto the manufacturing platform within six months.

This platform merges all the technologies needed to carry out the operations in the unit.

Cellares CEO Fabian Gerlinghaus stated: “The creation of the first IDMO marks the beginning of a new era, in which cell therapies will finally be able to reach those in need. 

“We’ve developed integrated technologies for the entire drug development and manufacturing lifecycle. 

“Now we’re leveraging these technologies to offer global manufacturing services for the living drugs of the 21st century.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.